ALNYLAM PHARMACEUTICALS INC

Alnylam’s Rule 144 insider sale is routine, yet it highlights key biotech trends—tax‑planning, reimbursement hurdles, and patient‑centric delivery—shaping future growth.

Alnylam’s 2026 Form 144 sale of 1,758 units shows routine insider liquidity and tax strategy, while its RNA‑therapeutics focus keeps it poised for long‑term growth.

City Therapeutics, led by former Alnylam CEO John Maraganore, seeks a Nasdaq IPO to fund RNAi trials for thromboembolism and Stargardt disease, showcasing strategic funding and cross‑disease potential in the RNAi biopharma space.

Alnylam’s RNAi breakthrough for ATTR cardiomyopathy shows real mortality reduction and cost‑effective outcomes—setting the stage for value‑based pricing and market leadership.

Alnylam’s new RNAi data show vutrisiran and zilebesiran delivering powerful, safe heart‑health benefits—from reducing amyloidosis‑related cardiac events to cutting uncontrolled hypertension by 12 mm Hg.

Alnylam’s RNA‑i data at ESC could reshape cardiovascular reimbursement, showing mortality reductions, cost savings, and investor confidence for a new era of biologic therapy.

Alnylam’s Q2 2026 results turn a net loss into $164 M profit, powered by a 37 % jump in AMVUTTRA sales, yet a revised revenue outlook and market drop expose risks and opportunities for growth.

Alnylam strengthens its RNA‑medicine pipeline by adding Dr. Laura Sepp‑Lorenzino to the Scientific Advisory Board, boosting CRISPR‑RNAi expertise and clinical‑trial strategy.

Alnylam’s late‑stage HCM trial setback drops shares, yet its diversified RNAi pipeline and strong oncology prospects keep investor optimism alive.

Alnylam boosts its R&D pipeline with a tech partnership and milestone‑based licensing, accelerating discovery, diversifying therapy focus, and strengthening cash flow.